ArticleEvidence-based complementary and alternative medicine : eCAM2014
The Effect of Mushroom Beta-Glucans from Solid Culture of Ganoderma lucidum on Inhibition of the Primary Tumor Metastasis.
Article in Evidence-based complementary and alternative medicine : eCAM, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Higher Mushroom Consumption Is Associated with Lower Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies.Advances in nutrition (Bethesda, Md.) · 2021Pooled it
- Pooled it
- Recent Advances in the Preparation, Structure, and Biological Activities of β-Glucan fromFoods (Basel, Switzerland) · 2023Review
- Immunomodulatory activity of extracts from five edible basidiomycetes mushrooms in Wistar albino rats.Scientific reports · 2022Article
- Fermentation WithFrontiers in nutrition · 2022Article
- Effects of Medicinal Fungi-Derived β-Glucan on Tumor Progression.Journal of fungi (Basel, Switzerland) · 2021Review
- Mushroom-Derived Bioactive Molecules as Immunotherapeutic Agents: A Review.Molecules (Basel, Switzerland) · 2021Review
- Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.Molecules (Basel, Switzerland) · 2021Review
- Taxonomy, Diversity and Cultivation of the Oudemansielloid/Xeruloid TaxaJournal of fungi (Basel, Switzerland) · 2021Review
- Medicinal Properties and Bioactive Compounds from Wild Mushrooms Native to North America.Molecules (Basel, Switzerland) · 2021Review
- Optimal concentration of necrostatin-1 for protecting against hippocampal neuronal damage in mice with status epilepticus.Neural regeneration research · 2020Article
- Influence of Maitake (BioMed research international · 2020Article
- Assessment of Polysaccharides from Mycelia of genus Ganoderma by Mid-Infrared and Near-Infrared Spectroscopy.Scientific reports · 2018Article
- Potential of Mushroom Compounds as Immunomodulators in Cancer Immunotherapy: A Review.Evidence-based complementary and alternative medicine : eCAM · 2018Review
- Lentinan from shiitake selectively attenuates AIM2 and non-canonical inflammasome activation while inducing pro-inflammatory cytokine production.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the effect of mushroom beta-glucans (MBGS) derived from solid culture of Ganoderma lucidum on tumor inhibition by examining size of the primary tumor and rate of metastasis in Lewis lung carcinoma (LLC) bearing mice (C57BL/6), given oral administration of MBGS with radiation therapy. A previous result showed that MBGS enhances NK cell-mediated cytotoxicity in mice without LLC bearing in advance. Furthermore, applications of MBGS in conjunction with radiation therapy were effective in controlling tumor growth, and rate of metastasis, life threatening, and can potentially serve as a protective factor for wounds and hair loss that resulted from the overgrowth of primary tumor in LLC bearing mice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.